The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma
- PMID: 34843751
- DOI: 10.1016/j.jhep.2021.11.021
The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma
Keywords: Immune checkpoint inhibitors; liver cancer; prognosis.
Conflict of interest statement
Conflict of interest Giuseppe Cabibbo has served as a consultant or on advisory boards for Bayer, Eisai, and Ipsen. Amit Singal has served as a consultant or on advisory boards for Bayer, Wako Diagnostics, Exact Sciences, Roche, Glycotest, and GRAIL.
Comment on
-
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12. J Hepatol. 2022. PMID: 34648895
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical